We distribute our research widely to institutional and retail investors through various channels, including our proprietary database, website, and other platforms (such as Bloomberg, Thomson Reuters and Factset).

We are fully MiFID II compliant. Our research is paid for by our corporate clients, and we do not carry out any execution business.

Published reports can be obtained by searching our Research Library below, or directly from the relevant Company Pages.

Advanced search
Date range (dd-mm-yyyy)

MaxCyte

Editas deal marks sixth commercial licence

Update | 07 October 2019

Hutchison China MediTech

ESMO 2019: surufatinib epNET PFS benefit confirmed

Update | 03 October 2019

Mereo BioPharma

Entering an important 12 month period

Update | 19 September 2019

MaxCyte

Consistent solid delivery

Update | 19 September 2019

Nexstim

Voluntary loan repayments remove Kreos uncertainty

Lighthouse | 17 September 2019

Hutchison China MediTech

WCLC 2019: detailed FALUCA data disclosed

Update | 11 September 2019

Scancell

A sweet source of financing

Update | 04 September 2019

Scancell

SCIB1 Phase II study starts in UK

Update | 21 August 2019

Nexstim

Promising progress with NBT

Update | 20 August 2019

BerGenBio

Refining the route ahead

Lighthouse | 20 August 2019
199 results found.